



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/990,049	11/21/2001	William Ford	450117-03449	1484
20999	7590	03/09/2004	EXAMINER	
FROMMER LAWRENCE & HAUG 745 FIFTH AVENUE- 10TH FL. NEW YORK, NY 10151			NAFF, DAVID M	
			ART UNIT	PAPER NUMBER
			1651	

DATE MAILED: 03/09/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

Application No.

09/990,049

Applicant(s)

FORD ET AL.

Examiner

David M. Naff

Art Unit

1651

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 12/15/03.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 25-47 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 25-47 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

***Response to Amendment***

The amendment of 12/15/03 amended the specification, canceled claims 1-24 and added new claims 25-47.

Claims examined on the merits are 25-47, which are all claims in  
5 the application.

***Claim Objections***

Claims 26-39 are objected to because of the following informalities: the claims are dependent on canceled claim 1, or dependent on a claim that is dependent on canceled claim 1.  
10 Appropriate correction is required.

***Claim Rejections - 35 USC § 112***

Claims 25-47 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the  
15 invention.

In claim 25, line 9, and where required in other claims, the meaning and scope of "interactive ligand binding" is uncertain, and it is unclear how this phenomena defines how formation of the conjugate occurs. The claim does not require a ligand, and it is uncertain how  
20 ligand binding can occur when no ligand is present. Additionally, by reciting "and/or" the claim encompasses formation of the conjugate by both metalation of bases and ligand binding. It is not seen how both can occur together.

In claim 27, the terms "oligonucleotides of DNA",  
25 "oligonucleotides of RNA", "polynucleotides of DNA", "polynucleotides

of RNA", "T-junctions of nucleic acids", and "non-nucleic acid polymer-nucleic acid block-copolymers" are uncertain as to meaning and scope. The specification does not define these terms, and the terms do not appear to have art recognized meanings. If these terms are  
5 known in the prior art and have an art recognized meaning, this should be established by evidence.

In line 4 of claim 31, reciting "phosphine or sulfide" is confusing since the sulfide is not the last member of the group. It appears "or" should be replaced with a comma. Additionally, in line  
10 5, "and" should be replaced with --- or --- since it does not appear that all of the members of the group are to be used together.

Claim 36 is unclear by not having clear antecedent basis for "the metal complex-nucleic acid composite". This term is not recited in claim 35 or claim 25. Claim 25 recites "metal complex-nucleic acid  
15 conjugate". If the composite is intended to be the conjugate, it is uncertain as to when in the process of claim 25 as further modified by claim 35 the conjugate is in the forms required by claim 36.

Claim 37 is unclear as to when in claim 25 as further modified by claim 35, metal complexes are treated as required. Are the metal  
20 complexes of claim 37 (line 1) the nucleic acid specific metal complex in line 3 of claim 25 or the non-conjugated metal complexes in line 5 of claim 25? Additionally, line 3 of claim 25 recites "metal complex" and not "metal complexes". If claim 37 is requiring treating the nucleic acid specific metal complex in line 3 of claim 25, it is

uncertain as to whether this treatment occurs before or after the complex is conjugated to a nucleic acid.

In line 3 of claim 37, "or" should be changed to --- and --- for a proper Markush group.

5 In line 3 of claim 38, reciting "magnetic and/or magnetized" is confusing since it is unclear as to the difference between being "magnetic" and "magnetized". It is uncertain as to how a metal can be magnetized and not magnetic or the converse. In line 4 of the claim, it is uncertain as to material represented by "B" and "P". If these  
10 are abbreviations, the full name should be recited, and provide support that B and P are known abbreviations for the name of the material. The Markush group of claim 38 is improper by reciting "or" in lines 3 and 4. The first "or" in line 3 should be changed to a comma, and the first "or" in line 4 changed to --- and ---.

15 In line 7 of claim 40, "or" should be replaced with --- and --- for a proper Markush group.

Claim 41 is unclear by requiring a linear array of metallic nanoparticles produced by the method of claim 40 since claim 40 is limited to producing a nanowire. There is not antecedent basis in  
20 claim 40 for producing a linear array of metallic nanoparticles.

Claim 46 is unclear by reciting "alloys" in line 2 since subsequently reciting "or" makes the metals alternative instead of together. It is suggested that "alloys" be replaced with --- and alloy ---.

***Response to Arguments***

Applicants urge that the claims must be read in light of the specification, and the claims become clear when the specification is read. However, the claims and not the specification define metes and  
5 bounds of the invention, and the claims must be sufficiently clear so one can know when the claimed invention is carried out. Otherwise, one cannot be sure as to when the claimed invention is infringed. Additionally, in certain instances noted above, the specification merely contains the language of the claims without further definition  
10 or explanation as to meaning and scope.

***Claim Rejections - 35 USC § 103***

Claims 25-31 and 33-47 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pompe et al (AR) in view of Singh et al (5,560,960) and Richter et al (AQ).

15 The claims are drawn to a process of producing a metal nanoparticle-nucleic composite by reacting a nucleic acid with a metal complex to produce a metal complex-nucleic acid conjugate by metalation of bases and/or interactive ligand binding, removing non-conjugated byproducts, and reacting the conjugate with a reducing  
20 agent to produce the metal nanoparticle-nucleic acid composite. The metal nanoparticle of the composite is catalytically active towards electroless metallisation. Also claimed is a metal nanoparticle-nucleic acid composite resulting from the process, a process of making a nanowire by treating the composite by electroless deposition of

metal, a nanowire resulting from the process, and a network or electronic circuit containing the nanowire.

Pompe et al disclose (page 1090, left col, second full paragraph) that Pt(II) and Pd(II) complexes such as cis-diamminedichloroplatinum  
5 attach to DNA bases to form stable monofunctional and bifunctional adducts. Further disclosed (third full paragraph of the left col) is that the Pt-DNA bond is not broken during reduction, and that Pt(II) and Pd(II) complexes attached to DNA double chain can act as nucleation centers for the growth of metal clusters. Also disclosed  
10 is carrying out metallization of DNA by adding DNA to Pd salt solution followed by adding a reducing agent, and obtaining clusters on the DNA of 3 to 5 nm in diameter in a few seconds after adding the reducing agent (paragraph bridging the cols, page 1090).

Singh et al disclose (paragraph bridging cols 1 and 2)  
15 precipitating nanometer-sized metal particles from solution within vesicles made from polymerizable phospholipids. Polymerized phospholipids are formed and added to a electroless plating solution. Before the electroless plating solution is added, palladium or platinum is provided on the inside surface of vesicles to function as  
20 a catalyst (col 3, lines 44-64). To insure that metal particles form only on the inside surface, any metal on the exterior surface of the vesicle is removed such as by using a chelating agent and gel filtering, or by passing the vesicles through an ion exchange column. Singh et al further disclose (col 5, line 18) using cobalt, nickel or  
25 iron when producing metal nanoparticles by electroless plating.

Richter et al disclose (page 508 and 510) metallization of DNA similar to Pompe et al and disclose formation of clusters of 1-5 nm diameter on DNA (page 508, left col, third full paragraph).

It would have been obvious to attach cis-diamminedichloroplatinum to DNA as disclosed by Pompe et al, and then use a reducing agent to obtain DNA containing attached platinum metal catalysis for use in electroless deposition of metal on the DNA as suggested by Singh et al subjecting vesicles containing Pd or Pt to electroless metal deposition and as suggested by Pompe et al carrying out metallization of DNA by treating a DNA solution with a Pd salt solution, and then adding a reducing agent to form metal clusters on the DNA. Removing non-attached metal complex from the DNA before electroless metallization would have been obvious to prevent the non-attached metal complex from forming metal particles as suggested by Singh et al removing metal from the exterior of vesicles to prevent metal particles from being formed on the vesicles exterior surface. The objective of Pompe et al is to obtain metal clusters on the DNA and not at other places, and to accomplish this one would obviously have to remove none attached metal complex before electroless metallization. It would have been apparent from Richter et al that metal clusters of 1-5 nm diameter can be obtained, and it would have been obvious to produce clusters not thicker than DNA since this is an objective of Pompe et al (page 1090, left col, first full paragraph). Reacting DNA with cis-diamminedichloroplatinum as disclosed by Pompe et al followed by reducing as set forth above will inherently result



in metallization of bases, and provide a metal nanoparticle active towards electroless metallization. When carrying out metallization of DNA as set forth above, it would have been obvious to form a nanowire since Pompe et al (page 1090, right col, lines 1-10) and Richter et al (paragraph bridging pages 508 and 509) obtain a nanowire. Using the nanowire in an electronic circuit would have been obvious since metal wires are conventionally used in such circuits. The metallization of Pompe et al and Richter et al is controlled since they disclose controlling the time of metallization to control the size of clusters. The use of cobalt, nickel or iron when producing metal nanoparticles by electroless plating as disclosed by Singh et al would have suggested using a electroless plating solution as in claim 38.

***Response to Arguments***

Applicants point out that a feature of the invention is the initial direct binding of a metal complex to the nucleic acid. However, as noted above, Pompe et al disclose binding cis-diamminedichloroplatinum to DNA, and suggest that metal of the resulting conjugate can act as a nucleation center for the growth of metal clusters.

Applicants urge that neither Richter et al or Pompe et al disclose forming a nanowire. However, both Pompe et al and Richter et al disclose obtaining a nanowire. See Pompe et al (page 1090, right col, lines 1-10) and Richter et al (paragraph bridging pages 508 and 509).

Applicants urge that Pompe et al and Richter et al produce nanoparticles substantially wider than DNA. However, the clusters of Richter et al can be 1-5 nm in width. The width of DNA is 2 nm. An objective of Pompe et al is to obtain more finer and more homogeneous metallization to improve wire conductivity and keep it not thicker than nonmetallized DNA (page 1090, left col, first full paragraph). Additionally, in claim 34 the metal nanoparticle size is smaller than 3 nm. Slightly less than 3 nm is wider than 2 nm DNA, and is not significantly different from 3 nm disclosed by Pompe et al and Richter et al.

***Claim Rejections - 35 USC § 103***

Claim 32 is rejected under 35 U.S.C. 103(a) as being unpatentable over the references as applied to claims 25-31 and 33-47 above, and further in view of Newsman et al (5,670,680).

The claim requires a gaseous reducing agent.

Singh et al disclose using hydrogenation (col 4, line 57) for reducing metal ions to produce metals in a process of producing metal nanoparticles by electroless plating.

Newman et al disclose using hydrogen gas for hydrogenation in producing metal complexes.

It would have been obvious to use hydrogen gas as a reducing agent to reduce the metal of a conjugate of a metal complex and DNA disclosed by Pompe et al as suggested by Singh et al and Newman et al.

***Double Patenting***

Claims 25-47 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-22 and 24-35 of copending Application No. 10/210,812 in view of Singh et al.

The claims of the copending application require metallization of a nucleic acid to produce a metal nanoparticle-nucleic acid composite.

It would have been obvious in view of Singh et al for the type of reasons set forth above to remove unattached metal complex before treatment with a reducing agent in the process of copending application claims for metallization of DNA. The presence of extraneous metal complex will obviously be a contaminant that can interfere with subsequent reactions.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

***Response to Arguments***

Applicants' argument that the copending application claims do not remove non-conjugated metal complex is unpersuasive since the removal of metal complex other than at a desired site for depositing metal would have been suggested by Singh et al.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David M. Naff whose telephone number is 571-272-0920. The examiner can normally be reached on Monday-Friday 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mike Wityshyn can be reached on 571-272-0926. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

5 Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For  
10 more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

15



David M. Naff  
Primary Examiner  
Art Unit 1651

DMN  
20 3/8/04